| NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 55513-0206-21 | 55513-0206 | Bevacizumab-awwb | MVASI | 100.0 mg/4mL, 100.0 mg/4mL | Immunotherapy | Monoclonal Antibody | VEGFR | Intravenous | Jun 27, 2025 | In Use | |
| 50242-0333-01 | 50242-0333 | Trastuzumab | Herceptin | Immunotherapy | Monoclonal Antibody | HER2 | Feb 10, 2017 | Feb 10, 2017 | No Longer Used | ||
| 55513-0224-01 | 55513-0224 | Rituximab-arrx | Riabni | 100.0 mg/10mL | Immunotherapy | Monoclonal Antibody | CD20 | Intravenous | Jan 6, 2021 | In Use | |
| 55513-0141-21 | 55513-0141 | trastuzumab-anns | Kanjinti | 150.0 mg/7.15mL | Immunotherapy | Monoclonal Antibody | HER2 | Intravenous | Jul 1, 2025 | In Use | |
| 57894-0502-20 | 57894-0502 | Daratumumab | Darzalex | 100.0 mg/5mL | Immunotherapy | Monoclonal Antibody | CD38 | Intravenous | Nov 16, 2015 | Nov 30, 2026 | In Use |
| 83257-0010-11 | 83257-0010 | Bevacizumab-nwgd | JOBEVNE | 25.0 mg/mL | Immunotherapy | Monoclonal Antibody | VEGFR | Intravenous | Apr 10, 2025 | In Use | |
| 83257-0009-11 | 83257-0009 | Bevacizumab-nwgd | JOBEVNE | 25.0 mg/mL | Immunotherapy | Monoclonal Antibody | VEGFR | Intravenous | Apr 10, 2025 | In Use | |
| 69448-0016-11 | 69448-0016 | Trastuzumab-strf | HERCESSI | 420.0 mg/20mL | Immunotherapy | Monoclonal Antibody | HER2 | Intravenous | Jan 1, 2025 | In Use | |
| 50242-0145-01 | 50242-0145 | Pertuzumab | Perjeta | 30.0 mg/mL | Immunotherapy | Monoclonal Antibody | HER2 | Intravenous | Jun 8, 2012 | In Use | |
| 65219-0668-01 | 65219-0668 | Denosumab | CONEXXENCE | 60.0 mg/mL | Immunotherapy | Monoclonal Antibody | RANKL | Subcutaneous | Jun 30, 2025 | In Use | |
| 57894-0505-05 | 57894-0505 | Daratumumab | Darzalex IV | 100.0 mg/5mL | Immunotherapy | Monoclonal Antibody | CD38 | Intravenous | Oct 15, 2021 | In Use | |
| 00069-0305-01 | 00069-0305 | Trastuzumab-qyyp | Trazimera | 420.0 mg/20 mL | Immunotherapy | Monoclonal Antibody | HER2 | Intravenous | Feb 24, 2020 | In Use | |
| 78206-0193-01 | 78206-0193 | Denosumab | BILDYOS | 60.0 mg/mL | Immunotherapy | Monoclonal Antibody | RANKL | Subcutaneous | Sep 11, 2025 | In Use | |
| 58468-0357-03 | 58468-0357 | Alemtuzumab | Campath | 30.0 mg/mL | Immunotherapy | Monoclonal Antibody | CD52 | Intravenous | Nov 30, 2009 | In Use | |
| 50242-0053-06 | 50242-0053 | Rituximab | Rituxan | 10.0 mg/mL | Immunotherapy | Monoclonal Antibody | CD20 | Intravenous | Nov 26, 1997 | In Use | |
| 00069-0342-01 | 00069-0342 | Bevacizumab-bvzr | Zirabev | 400.0 mg/16mL | Immunotherapy | Monoclonal Antibody | VEGFR | Intravenous | Jan 13, 2020 | In Use | |
| 83654-0105-01 | 83654-0105 | Penpulimab | Penpulimab | 100.0 mg/10mL | Immunotherapy | Monoclonal Antibody | PD-1 | Intravenous | Apr 23, 2025 | In Use | |
| 83257-0001-11 | 83257-0001 | Trastuzumab-dkst | OGIVRI | 150.0 mg/7.4mL | Immunotherapy | Monoclonal Antibody | HER2 | Intravenous | Oct 1, 2023 | In Use | |
| 72606-0038-01 | 72606-0038 | Denosumab-bmwo | Osenvelt | 120.0 mg/1.7mL | Immunotherapy | Monoclonal Antibody | RANKL | Subcutaneous | Jul 2, 2025 | In Use | |
| 50242-0159-01 | 50242-0159 | Mosunetuzumab | Lunsumio | 1.0 mg/mL | Immunotherapy | Monoclonal Antibody | CD20, CD3 | Intravenous | Dec 22, 2022 | In Use | |
| 83257-0004-12 | 83257-0004 | Trastuzumab-dkst | OGIVRI | Immunotherapy | Monoclonal Antibody | HER2 | Oct 1, 2023 | In Use | |||
| 50242-0134-68 | 50242-0134 | Trastuzumab | Herceptin | Immunotherapy | Monoclonal Antibody | HER2 | Sep 25, 1998 | Apr 30, 2019 | No Longer Used | ||
| 00173-0821-02 | 00173-0821 | Ofatumumab | Arzerra | 20.0 mg/mL | Immunotherapy | Monoclonal Antibody | CD20 | Intravenous | Jul 22, 2011 | Aug 31, 2017 | No Longer Used |
| 61314-0240-63 | 61314-0240 | Denosumab | JUBBONTI | 60.0 mg/mL | Immunotherapy | Monoclonal Antibody | RANKL | Subcutaneous | Jun 2, 2025 | In Use | |
| 72606-0037-01 | 72606-0037 | Denosumab-bmwo | Stoboclo | 60.0 mg/mL | Immunotherapy | Monoclonal Antibody | RANKL | Subcutaneous | Jul 2, 2025 | In Use |
Found 11888 results — Export these results
Home